The average annual drug cost for the 16 orphan drugs also showed an increasing trend from 2018 to 2021, indicating that the growth in usage has driven the increase in drug costs after their inclusion in the NRDL.
← all excerpts
Utilization and affordability of health insurance coverage for rare disease drugs in a first-tier city in Northeast China from 2018 to 2021: a study based on the health insurance claims database.
1
—
—